{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:41:14Z","timestamp":1792406474571,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022600","name":"Taipei Municipal Wan Fang Hospital","doi-asserted-by":"publisher","award":["114-wf-eva-40"],"award-info":[{"award-number":["114-wf-eva-40"]}],"id":[{"id":"10.13039\/501100022600","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114-2320-B-038 -043 -MY3"],"award-info":[{"award-number":["NSTC 114-2320-B-038 -043 -MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.tranon.2026.103074","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:27:55Z","timestamp":1791937675000},"page":"103074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Soluble N-terminal EphA2 fragment as a diagnostic biomarker and functional mediator of tumor progression in triple-negative breast cancer"],"prefix":"10.1016","volume":"74","author":[{"given":"Tsai-Yu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6711-5820","authenticated-orcid":false,"given":"Fu-Ling","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-2446","authenticated-orcid":false,"given":"Shang-Ju","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Huei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Chen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4221-6809","authenticated-orcid":false,"given":"Ming-Hui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng-Chang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-9121","authenticated-orcid":false,"given":"Wei-Chun","family":"HuangFu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Sheng","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2667-9029","authenticated-orcid":false,"given":"Yu-Ching","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.tranon.2026.103074_bib0001","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.tranon.2026.103074_bib0002","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.tranon.2026.103074_bib0003","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/PAP.0000000000000084","article-title":"Triple-negative breast carcinoma: morphologic and molecular subtypes","volume":"22","author":"Bose","year":"2015","journal-title":"Adv. Anat. Pathol."},{"issue":"3","key":"10.1016\/j.tranon.2026.103074_bib0004","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/0897190012442062","article-title":"Triple negative breast cancer: a brief review of its characteristics and treatment options","volume":"25","author":"Griffiths","year":"2012","journal-title":"J. Pharm. Pr."},{"issue":"9","key":"10.1016\/j.tranon.2026.103074_bib0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2026.103074_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.545","article-title":"Specific detection of soluble EphA2 fragments in blood as a new biomarker for pancreatic cancer","volume":"8","author":"Koshikawa","year":"2017","journal-title":"Cell Death. Dis."},{"issue":"2","key":"10.1016\/j.tranon.2026.103074_bib0007","first-page":"613","article-title":"Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival","volume":"9","author":"Kinch","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"7\u20138","key":"10.1016\/j.tranon.2026.103074_bib0008","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10585-006-9045-7","article-title":"Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status","volume":"23","author":"Mudali","year":"2007","journal-title":"Clin. Exp. Metastasis."},{"issue":"4","key":"10.1016\/j.tranon.2026.103074_bib0009","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T","article-title":"Overexpression of the EphA2 tyrosine kinase in prostate cancer","volume":"41","author":"Walker-Daniels","year":"1999","journal-title":"Prostate"},{"issue":"10","key":"10.1016\/j.tranon.2026.103074_bib0010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1541-7786.MCR-05-0056","article-title":"EphA2 as a novel molecular marker and target in glioblastoma multiforme","volume":"3","author":"Wykosky","year":"2005","journal-title":"Mol. Cancer Res."},{"issue":"5","key":"10.1016\/j.tranon.2026.103074_bib0011","first-page":"2301","article-title":"EphA2 overexpression causes tumorigenesis of mammary epithelial cells","volume":"61","author":"Zelinski","year":"2001","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2026.103074_bib0012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41568-023-00634-x","article-title":"Eph receptors and ephrins in cancer progression","volume":"24","author":"Pasquale","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"16","key":"10.1016\/j.tranon.2026.103074_bib0013","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1158\/0008-5472.CAN-14-2798","article-title":"Proteolysis of EphA2 converts it from a tumor suppressor to an oncoprotein","volume":"75","author":"Koshikawa","year":"2015","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.tranon.2026.103074_bib0014","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.21873\/anticanres.12722","article-title":"Activated EphA2 processing by MT1-MMP is involved in malignant transformation of ovarian tumours In vivo","volume":"38","author":"Takahashi","year":"2018","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.tranon.2026.103074_bib0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0014-5793(01)02985-4","article-title":"Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane-type-1 matrix metalloproteinase (MT1-MMP)","volume":"507","author":"Gingras","year":"2001","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.tranon.2026.103074_bib0016","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ccr.2005.07.005","article-title":"A conditional feedback loop regulates Ras activity through EphA2","volume":"8","author":"Macrae","year":"2005","journal-title":"Cancer Cell."},{"issue":"2","key":"10.1016\/j.tranon.2026.103074_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12020366","article-title":"EPHA2, EPHA4, and EPHA7 expression in triple-negative breast cancer","volume":"12","author":"Nikas","year":"2022","journal-title":"Diagnostics"},{"issue":"11","key":"10.1016\/j.tranon.2026.103074_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e21774","article-title":"Effectiveness of anti-erythropoietin producing hepatocellular receptor type-A2 antibody in pancreatic cancer treatment","volume":"9","author":"Chang","year":"2023","journal-title":"Heliyon"},{"issue":"1\u20132","key":"10.1016\/j.tranon.2026.103074_bib0019","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0022-1759(00)00221-0","article-title":"Methods for the generation of chicken monoclonal antibody fragments by phage display","volume":"242","author":"Andris-Widhopf","year":"2000","journal-title":"J. Immunol. Meth."},{"issue":"1","key":"10.1016\/j.tranon.2026.103074_bib0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.103074_bib0021","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s12964-024-01811-7","article-title":"Targeting the EphA2 pathway: could it be the way for bone sarcomas?","volume":"22","author":"Giordano","year":"2024","journal-title":"Cell Commun. Signal."},{"issue":"7","key":"10.1016\/j.tranon.2026.103074_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110345","article-title":"Largescale multicenter study of a serum metabolite biomarker panel for the diagnosis of breast cancer","volume":"27","author":"Wang","year":"2024","journal-title":"iScience"},{"issue":"9","key":"10.1016\/j.tranon.2026.103074_bib0023","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1158\/2767-9764.CRC-23-0087","article-title":"EphA2 Proteolytic fragment as a sensitive diagnostic biomarker for very early-stage pancreatic ductal carcinoma","volume":"3","author":"Sato","year":"2023","journal-title":"Cancer Res. Commun."},{"issue":"6","key":"10.1016\/j.tranon.2026.103074_bib0024","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","article-title":"A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes","volume":"10","author":"Neve","year":"2006","journal-title":"Cancer Cell."},{"issue":"2","key":"10.1016\/j.tranon.2026.103074_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.tranon.2026.103074_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103870","article-title":"Ligands with different dimeric configurations potently activate the EphA2 receptor and reveal its potential for biased signaling","volume":"25","author":"Gomez-Soler","year":"2022","journal-title":"iScience"},{"issue":"14","key":"10.1016\/j.tranon.2026.103074_bib0027","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/s41388-021-01714-8","article-title":"Oncogenic functions and therapeutic targeting of EphA2 in cancer","volume":"40","author":"Wilson","year":"2021","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.tranon.2026.103074_bib0028","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1039\/c2ib20215h","article-title":"Evaluation of the shear force of single cancer cells by vertically aligned carbon nanotubes suitable for metastasis diagnosis","volume":"5","author":"Abdolahad","year":"2013","journal-title":"Integr. Biol."},{"issue":"2","key":"10.1016\/j.tranon.2026.103074_bib0029","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/35000008","article-title":"Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation","volume":"2","author":"Miao","year":"2000","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.tranon.2026.103074_bib0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1083\/jcb.201205176","article-title":"EphA2 cleavage by MT1-MMP triggers single cancer cell invasion via homotypic cell repulsion","volume":"201","author":"Sugiyama","year":"2013","journal-title":"J. Cell Biol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326004109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326004109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:50:14Z","timestamp":1792403414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326004109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":30,"alternative-id":["S1936523326004109"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103074","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble N-terminal EphA2 fragment as a diagnostic biomarker and functional mediator of tumor progression in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103074"}}